Paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer from paclitaxel side effects Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr G Thomas Budd presents data on a phase III randomised clinical trial that found low-dose weekly administration of paclitaxel and standard dose, every two weeks administration, resulted in equal progression-free survival for women with higher-risk early-stage breast cancer who have undergone surgery.nnHowever, researchers found that certain side effects were more common with the every two weeks regimen, suggesting the weekly schedule may be preferable.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)